Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder characterized by the formation of sterile pustules on the palms and soles. At our company, we specialize in the development of drugs and therapies for autoimmune diseases and inflammation, including palmoplantar pustulosis.
Overview of Palmoplantar Pustulosis
Palmoplantar pustulosis is a relatively uncommon dermatological condition that primarily affects the palms and soles. It is characterized by the formation of sterile pustules, which can be painful and cause significant impairment in daily activities. It is considered a variant of psoriasis, although its exact etiology remains unclear. Studies have shown that genetic predisposition, including HLA-Cw6 and IL36RN gene mutations, play a role in disease susceptibility. Additionally, dysregulation of immune cells, such as T cells and neutrophils, and the release of pro-inflammatory cytokines, including IL-17 and IL-23, contribute to the inflammatory process in PPP.
Abnormal expression of various molecules involved in epidermal differentiation and keratinocyte proliferation, such as keratin 16 and keratin 17, has also been observed in PPP lesions. These alterations in the skin barrier function further perpetuate the inflammatory response.
Fig.1 Histopathological changes from vesicle to pustule and the putative factors involved in the process. (Murakami M., et al., 2020)
Drug Discovery and Development for Palmoplantar Pustulosis
Topical therapies, such as potent corticosteroids, calcipotriol, and tar preparations, are commonly used as the first-line therapeutic for mild to moderate PPP. However, these may provide limited efficacy in severe cases. Systemic therapies, including retinoids, methotrexate, and cyclosporine, are considered for patients with severe and refractory PPP. Emerging targeted therapies have shown promise in the therapeutics of PPP. These include anti-IL-17 agents, such as secukinumab, and anti-IL-23 agents, such as guselkumab. These agents specifically target key cytokines involved in the pathogenesis of PPP, providing a more targeted and effective therapeutic approach.
Our organization takes great pride in our wide range of therapeutic development platforms, which enable us to offer customized solutions for the development of therapies for palmoplantar pustulosis. If you would like to gain a deeper understanding of the services we offer, we warmly invite you to explore the link provided for more detailed information.
Small Molecule Drug
Probiotics Therapy
Therapeutic Antibody
Cell Therapy
Gene Therapy
Therapeutics Development
Our Services
To enhance our understanding of palmoplantar pustulosis pathogenesis and develop effective therapeutics, we have meticulously developed robust animal models and in vitro models that faithfully replicate the key characteristics of the disease. These cutting-edge models serve as invaluable tools, enabling us to thoroughly evaluate the safety and efficacy of potential drug candidates, thus expediting the development of novel and targeted therapies for palmoplantar pustulosis.
PPP Tonsil Cell Transfer Models
By intraperitoneally administering mononuclear cells derived from the excised tonsils of PPP patients to SCID mice, we observe the development of hair loss, skin rash, and the presence of human IgG and anti-keratin antibodies in the mice.
PPP Tonsil Cell Transfer and Skin Grafting Models
To further investigate the response of amygdala cells in PPP patients to their own palmoplantar skin, we have developed a model utilizing skin grafts in addition to tonsil cell transfer in SCID mice.
PPP Tonsil Cell Transfer and HSP Administration Models
Heat shock proteins (HSPs) have been implicated in the pathogenesis of PPP. To investigate this further, we have developed an animal model that combines tonsil cell transfer in SCID mice with the administration of HSPs to the skin.
PPP In Vitro Models
Our in vitro model development services for palmoplantar pustulosis include cell-based model development, such as primary keratinocyte isolation and culture, and organoid model development, such as skin organoids.
Why Choose Us?
At our company, we have established ourselves as experts in offering comprehensive diagnostics and therapy development services specifically tailored for palmoplantar pustulosis (PPP). In addition to the aforementioned range of services and models, we also specialize in tailoring customized solutions and developing disease models that precisely align with your distinctive requirements. Should our array of services capture your interest, we warmly encourage you to reach out to us without hesitation.
References
- Murakami Masamoto, and Tadashi Terui. "Palmoplantar pustulosis: current understanding of disease definition and pathomechanism." Journal of Dermatological Science 98.1 (2020): 13-19.
- Misiak-Galazka Magdalena, Joanna Zozula, and Lidia Rudnicka. "Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments." American Journal of Clinical Dermatology 21 (2020): 355-370.